Lu-DOTA-TATE

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

GlioblastomaExtensive-Stage Small-Cell Lung CancerMetastatic Neuroendocrine Prostate Cancer

160 competitors in Glioblastoma

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

582

Keytruda

Merck & Co.

Phase 3

243

Opdivo

Bristol-Myers Squibb

Phase 3

184

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1605

Yervoy

Bristol-Myers Squibb

Phase 3

116

Ceenu

AAzurity Pharmaceuticals

Phase 3

217

Antabuse

Teva

Phase 3

58

Feraheme

AAzurity Pharmaceuticals

Phase 3

49

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

410

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

3Show 45 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Neuroendocrine Tumors2 trials

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Unknown status·PPeking Union Medical College Hospital·Phase 1·NCT03478358·60 enrolled

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

Completed·LLund University Hospital·Phase 2·NCT01456078·60 enrolled

Glioblastoma1 trial

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent

Active, not recruiting·Novartis·Phase 1·NCT05109728·65 enrolled

Extensive-stage Small-cell Lung Cancer1 trial

A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase

Active, not recruiting·Novartis·Preclinical·NCT05142696·55 enrolled

Carcinoma, Neuroendocrine1 trial

An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Suspended·AAHS Cancer Control Alberta·Phase 2·NCT01876771·413 enrolled

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting·Novartis·Phase 1·NCT06379217·31 enrolled

Details

Drug Info

Related News